Trivobiwin 1mg/500mg/0.2mg Tablet
Marketer
Ranmarc Labs
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.2mg)
Overview Trivobiwin 1mg/500mg/0.2mg Tablet
Diabetacomb 1mg/500mg/0.2mg tablets are classified as antidiabetic medications. This combination therapy is indicated for managing type 2 diabetes in adults, facilitating improved blood glucose regulation. Diabetacomb 1mg/500mg/0.2mg tablets should be ingested with food, consistently at the same time daily for optimal efficacy. Dosage adjustments are determined by your physician based on your blood glucose response. Continued use is crucial, even with controlled blood sugar; abrupt cessation without medical consultation risks elevated blood glucose, potentially leading to kidney complications, vision impairment, neuropathy, and limb loss. This medication complements a holistic diabetes management plan encompassing diet, exercise, and weight management as directed by your doctor. Lifestyle modifications significantly contribute to diabetes control. Hypoglycemia (low blood glucose) is a prevalent side effect, characterized by symptoms such as sweating, lightheadedness, headache, and tremors. Prompt glucose intake (e.g., sugary snacks, fruit juice) is essential for management. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Additional potential side effects include altered taste perception, nausea, diarrhea, abdominal discomfort, cephalalgia, edema, blurred vision, fractures, and upper respiratory infections. Weight gain may occur in some individuals. This medication is contraindicated in type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment. Prior heart disease should be disclosed to your physician before initiating treatment. Consult your doctor before use during pregnancy or breastfeeding. Regular blood glucose monitoring, along with periodic blood tests to assess blood cell counts and liver function, are recommended.
Primary Ingredients of Trivobiwin 1mg/500mg/0.2mg Tablet
No text provided. Please provide the text you would like me to rephrase.
Uses of Trivobiwin 1mg/500mg/0.2mg Tablet
Managing type 2 diabetes
Major Benefits of Trivobiwin 1mg/500mg/0.2mg Tablet:
Your physician will determine the correct dosage and treatment length for this medication. Ingest the Trivobiwin 1mg/500mg/0.2mg tablet whole; do not chew, crush, or divide it. Administer on an empty stomach.
Common Side effects of Trivobiwin 1mg/500mg/0.2mg Tablet:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Trivobiwin 1mg/500mg/0.2mg Tablet:
Your physician will determine the correct dosage and treatment length for this medication. Ingest the Trivobiwin 1mg/500mg/0.2mg Tablet whole; do not crush, chew, or divide it. Administer on an empty stomach.
How Trivobiwin 1mg/500mg/0.2mg Tablet works:
Each Trivobiwin 1mg/500mg/0.2mg tablet combines three distinct antidiabetic agents.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent use of alcohol and Trivobiwin 1mg/500mg/0.2mg tablets is contraindicated.
PregnancyCONSULT YOUR DOCTOR
The use of Trivobiwin 1mg/500mg/0.2mg Tablet during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the potential advantages against possible risks prior to prescribing. Physician consultation is advised.
Breast feedingCONSULT YOUR DOCTOR
The use of Trivobiwin 1mg/500mg/0.2mg tablets while breastfeeding is likely inadvisable. Available human data indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
Employing Trivobiwin 1mg/500mg/0.2mg Tablets in individuals with kidney impairment carries a significant risk and is best avoided. Medical advice is essential. Furthermore, its use is contraindicated in patients exhibiting severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Trivobiwin 1mg/500mg/0.2mg tablets cautiously, potentially requiring dosage modification. Medical advice is necessary. A reduced initial dose is typically prescribed for those with mild to moderate liver disease; however, its use is contraindicated in patients with severe hepatic dysfunction.
What if you forget to take Trivobiwin 1mg/500mg/0.2mg Tablet :
Should you forget to take a Trivobiwin 1mg/500mg/0.2mg Tablet, administer it at your earliest convenience. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Trivobiwin 1mg/500mg/0.2mg Tablet
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes Management |
3,018 People bought this recently